Iterum TherapeuticsITRM
ITRM
About: Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
Employees: 9
0
Funds holding %
of 7,299 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
0% more funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 1 (+0) [Q1 2025]
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
1.35% less ownership
Funds ownership: 4.53% [Q4 2024] → 3.17% (-1.35%) [Q1 2025]
22% less funds holding
Funds holding: 23 [Q4 2024] → 18 (-5) [Q1 2025]
39% less capital invested
Capital invested by funds: $2.2M [Q4 2024] → $1.35M (-$851K) [Q1 2025]
67% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 6
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$9
800%
upside
Avg. target
$9
800%
upside
High target
$9
800%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Joseph Pantginis | 800%upside $9 | Buy Assumed | 8 May 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
5 days ago
Iterum Therapeutics Announces Partnership for Commercialization Services
U.S. Commercial Launch of ORLYNVAH TM by Q4 2025; First Oral Penem Available in the U.S. Management to host a conference call at 4:30 p.m. ET today DUBLIN and CHICAGO, June 11, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum”), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported that it entered into a Product Commercialization Agreement (the “Agreement”) with EVERSANA Life Science Services, LLC (“EVERSANA”) for the commercialization of the Company's approved product, ORLYNVAHTM.
Neutral
GlobeNewsWire
4 weeks ago
Iterum Therapeutics Announces Extension of Term of Promissory Note
DUBLIN and CHICAGO, May 19, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum”), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported that Pfizer Inc. (“Pfizer”) has agreed to extend the term for payment of the regulatory milestone payment of $20.0 million until October 25, 2029.
Neutral
Seeking Alpha
1 month ago
Iterum Therapeutics plc (ITRM) Q1 2025 Earnings Call Transcript
Iterum Therapeutics plc (NASDAQ:ITRM ) Q1 2025 Earnings Conference Call May 13, 2025 8:30 AM ET Company Participants Louise Barrett - SVP, Legal Affairs Corey Fishman - Chief Executive Officer Judy Matthews - Chief Financial Officer Conference Call Participants Matthew Keller - H.C. Wainwright Operator Hello, everyone, and thank you for joining the Iterum Therapeutics plc First Quarter 2025 Earnings and Business Update Call.
Neutral
GlobeNewsWire
1 month ago
Iterum Therapeutics Reports First Quarter 2025 Financial Results
--Preparing for Potential Launch of ORLYNVAH TM by Q4 2025-- - -Extended Cash Runway into 2026-- --Company to host conference call today at 8:30amET-- DUBLIN, Ireland and CHICAGO, May 13, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the first quarter ended March 31, 2025. “Based on pre-commercialization work completed to date, we expect to be able to launch ORLYNVAHTM for the treatment of uncomplicated urinary tract infections (uUTIs) by the fourth quarter of this year,” said Corey Fishman, Iterum's Chief Executive Officer.
Neutral
GlobeNewsWire
1 month ago
Iterum Therapeutics to Report First Quarter 2025 Financial Results on May 13, 2025
DUBLIN, Ireland and CHICAGO, May 06, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Company), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company will release its first quarter 2025 financial results before the open of the U.S. financial markets on Tuesday, May 13, 2025. Management will host a conference call at 8:30 a.m.
Neutral
GlobeNewsWire
1 month ago
Iterum Therapeutics Announces Closing of $5 Million Registered Direct Offering of Ordinary Shares
DUBLIN, Ireland and CHICAGO, April 30, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today closed the previously announced purchase and sale of an aggregate of 5,555,556 ordinary shares (or pre-funded warrants in lieu thereof) at a purchase price of $0.90 per ordinary share (or pre-funded warrant in lieu thereof) in a registered direct offering (the Offering) with a single institutional investor.
Neutral
GlobeNewsWire
1 month ago
Iterum Therapeutics Announces $5 Million Registered Direct Offering of Ordinary Shares
DUBLIN, Ireland and CHICAGO, April 29, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that it has entered into a definitive agreement with a single institutional investor for the purchase and sale of an aggregate of 5,555,556 ordinary shares (or pre-funded warrants in lieu thereof) at a purchase price of $0.90 per ordinary share (or pre-funded warrant in lieu thereof) in a registered direct offering (the Offering). The closing of the Offering is expected to occur on or about April 30, 2025, subject to the satisfaction of customary closing conditions.
Neutral
GlobeNewsWire
2 months ago
Iterum Therapeutics Presented a Scientific Poster at ECCMID 2025 Highlighting the Impact of Age on Antibiotic Resistance and Efficacy of Antibiotics
DUBLIN and CHICAGO, April 14, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that one poster was presented at the 35th Annual European Congress of Clinical Microbiology and Infectious Disease (ECCMID) held in Vienna, Austria, from April 11-15, 2025.
Neutral
Seeking Alpha
4 months ago
Iterum Therapeutics plc (ITRM) Q4 2024 Earnings Call Transcript
Iterum Therapeutics plc (NASDAQ:ITRM ) Q4 2024 Earnings Conference Call February 7, 2025 8:30 AM ET Company Participants Louise Barrett - SVP, Legal Affairs Corey Fishman - CEO Judy Matthews - CFO Conference Call Participants Thomas Yip - H.C. Wainwright Operator Hello, everyone.
Neutral
GlobeNewsWire
4 months ago
Iterum Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
- -ORLYNVAH TM Approved by FDA in Q4 2024— - -Extended Cash Runway-- --Company to host conference call today at 8:30amET-- DUBLIN and CHICAGO, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the fourth quarter and year ended December 31, 2024. “While outreach to potential strategic partners is our priority and ongoing, we have begun pre-commercialization work to ensure ORLYNVAHTM is made available to patients as soon as possible to address the substantial unmet need for effective treatment options for uncomplicated urinary tract infections (uUTIs),” said Corey Fishman, Iterum's Chief Executive Officer.
Charts implemented using Lightweight Charts™